Feasibility study into the experimental application of advanced materials to reduce radiation backscatter in the high value radiotherapy planning and treatment market.

英国癌症研究中心（Cancer Research UK）的数据显示，仅在2013年，英国就有超过33万例癌症诊断。X射线CT、MRI和直线加速器系统广泛用于癌症放射治疗计划和治疗。Medibord Ltd生产专利放射治疗定位产品，全球医疗保健专业人员使用这些产品来准确和可重复地定位和治疗患者的癌细胞，这对有效治疗至关重要。根据技术和市场研究，Medibord已经确定了一种潜在的重大产品改进，通过确保成像和治疗不会导致额外的辐射暴露，可以进一步提高患者的长期结局。在许多情况下，这种额外的辐射是继发性癌症的原因。

Cancer Research UK has revealed that in the UK alone in 2013 there were in excess of 330,000 cancer diagnoses. X-ray CT, MRI and Linac systems are widely used in cancer radiotherapy planning and treatment. Medibord Ltd produces patented radiotherapy positioning products which are used by healthcare professionals worldwide to accurately and reproducibly locate and treat a patient’s cancerous cells which is critical for effective treatment. Based on technical and market research Medibord has identified a potentially significant product enhancement which could further enhance the long term outcomes for patients by ensuring that additional radiation exposure does not occur as a result of imaging and treatment. This additional radiation is responsible for secondary cancers in a number of cases.